Aptose Biosciences Inc.

Dozens of public biopharmaceutical companies have announced plans in 2025 to assess strategic alternatives after clinical trial setbacks or as cash stockpiles dwindled. Both ESSA Pharma and Elevation

A series of confirmed complete remissions at various doses in patients receiving Hanmi Pharmaceutical Co., Ltd. ’s in-house-developed innovative drug for acute myeloid leukemia (AML), HM43239, are mo

As more South Korean pharma companies seek to globalize and do cross-border license deals, licensing-related income and sales from overseas subsidiaries appear to be taking on greater weight in their

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. CJ CheilJedang Acquires Batavia To Expa